Your body makes glutathione. It just can't absorb the pill form. Our LipoSone™ liquid liposomes deliver the intact molecule into circulation — where a standard tablet leaves almost nothing behind.
Current batch sold through. Next production run is reserved for the notify list first.
Start today and your day-14 mark falls on . The clock is biological, not promotional.
Reduced L-glutathione is sealed inside a sunflower-derived phosphatidylcholine bilayer — soy-free, and built to mimic your own cell membranes.
That bilayer shields the tripeptide from the stomach acid and proteases that dismantle ordinary GSH tablets before absorption.
Plasma glutathione rose steadily across every measurement point in our head-to-head trial. The tablet arm stayed flat.
The intact glutathione tripeptide arrives in systemic circulation via LipoSone™ liquid liposomal delivery — ready for the body to use.
Glutathione is consumed continuously — by ordinary metabolism, by alcohol, by broken sleep, by hard training, by pollution, and simply by getting older. Replacement is the obvious answer, and for most people it quietly fails at the first step: the molecule is taken apart in the gut before it is ever absorbed.
The molecule works. The delivery is what fails.
A Penn State College of Medicine team gave healthy adults oral liposomal glutathione at 500 mg daily and drew blood at weeks one, two and four. This is the shape of the curve they recorded.
Whatever your glutathione status is today. In the published trial, this single number predicted almost everything that followed.
Blood glutathione was already elevated above baseline at the first measurement point — one week in, at 500 mg daily.
The high-water mark across every compartment measured: +40% whole blood, +28% red cells, +25% plasma. Oxidised-to-reduced ratio down 20%.
Levels remained above baseline through the end of the month. The authors flagged a possible drop in self-measured dosing late in the study — one reason we pre-dose the pump.
Across every time point, the change in glutathione correlated inversely with where a participant began — strongly, at r = 0.6 to 0.8. The further below the group you started, the further you climbed. If you have been running on a deficit for years, you are the profile with the most room to move.
In published human research on oral liposomal glutathione at this dose, blood was drawn at weeks one, two and four. Levels were already up at week one. Week two was the high-water mark, across every compartment measured.
Start a bottle today and your day-14 mark lands on . Every week you wait moves that date, and nothing else about it changes.
The Penn State team ran two arms — 500 mg and 1000 mg daily — and found no advantage to doubling. Several of the largest recorded changes came from the 500 mg group. The authors are careful to say the study was too small to settle the question, and so are we.
What it does tell you is that 500 mg is a serious, studied dose rather than a label decoration. That is the dose in every 7 mL serving of this bottle.
This is the finding most brands leave out, because it doesn't flatter everyone. Across every time point in the published trial, the size of the change correlated inversely with where a person began — strongly, at r = 0.6 to 0.8. The lower the starting point, the bigger the climb.
Which means the honest answer to “will this do much for me?” depends less on the product than on how long you've been running a deficit.
Each of these draws on your glutathione daily.
Tick what applies to you.
Twenty metabolically healthy adults, randomised evenly, 500 mg glutathione daily for seven days. Plasma measured by LC/MS-MS at day 0, 3 and 7 — LipoSone™ liquid liposomes against a standard glutathione tablet.
Incremental AUC vs. the tablet control
Meaningful plasma rise in the tablet arm across 7 days
Randomised, controlled, head-to-head design
We would rather you read this from us than find it yourself.
It tested a different commercial liposomal glutathione. We cite it as evidence about the delivery format and its timeline — never as evidence about our bottle.
Six people per dose arm. Small enough that the authors flag limited statistical power throughout.
The authors state plainly that placebo-controlled trials are still required to confirm specificity.
Funded by the manufacturer of the tested product, who also supplied it. Disclosed in the paper; disclosed here.
Healthy non-smokers. Findings may not transfer identically to younger or unhealthy populations.
The active reduced form — never oxidised GSSG, never a precursor you have to convert. 500 mg is the dose used in the published human work, where it matched a 1000 mg arm.
The delivery vehicle. A phospholipid shell that mirrors your own cell membranes and carries the intact tripeptide past the proteases that dismantle tablets.
“We use only the reduced (active) form of glutathione — not oxidised glutathione (GSSG) or precursors. The LipoSone™ shell prevents re-oxidation during storage and transit.”
In the month-long published trial at 500 mg and 1000 mg daily, no serious adverse effects were reported in either group, and none of the minor events recorded were attributed to the supplement. Compliance ran above 98% — people stayed on it because there was nothing to tolerate.
Opened bottle included. Glutathione status is a blood number, not a feeling — so we're not going to ask you to gamble on a sensation. Try it for a month. If you're not convinced, one email and it's refunded, no questions asked.
Standard glutathione tablets are broken down by proteolytic enzymes in the gut before reaching the bloodstream. Our human RCT confirmed zero meaningful plasma GSH increase in the tablet control group — versus a 7-day linear increase with LipoSone™.
One 7 mL serving daily. 500 mg reduced glutathione, delivered intact. Third-party tested, batch by batch.
